Associated Papers
Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision Medicine.
Tashkandi H et al.
Cancers, 2024
A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance.
Gorantla SP et al.
Molecular Oncology, 2024
Structure-guided selection of specificity determining positions in the human Kinome.
Moll M et al.
Bmc Genomics, 2016
Novel myelofibrosis treatment strategies: potential partners for combination therapies.
Stein BL et al.
Leukemia, 2014
Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.
Marty C et al.
Blood, 2014
A case of pediatric B-Lymphoblastic leukemia presenting with a t(9;12)(p24;q11.2) involving JAK2 and concomitant MLL rearrangement with apparent insertion at 6q27.
Tirado CA et al.
Biomarker Research, 2013
Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.
Marit MR et al.
Plos One, 2012
Select a paper to view details